Live
- They always want me to win, and now I feel lucky to have been offered a story like ‘Zebra’: Satyadev Kancharana
- ‘Democracy first, humanity first’: PM Modi in Guyana's parliament on two countries' similarities
- PKL Season 11: Telugu Titans register third straight win to top standings
- Is Pollution Contributing to Your COPD?
- NASA Unveils Underwater Robots for Exploring Jupiter's Moons
- Additional Central forces arrive in violence-hit Manipur
- AR Rahman and Saira Banu’s Divorce: Legal Insights into Common Issues in Bollywood Marriages
- 82.7 pc work completed in HPCL Rajasthan Refinery area: official
- Curfew relaxation extended in 5 Manipur districts on Friday
- Tab scam prompts Bengal govt to adopt caution over fund disbursement
UoH collaborates with UK based biotech company
Hyderabad: Hyderabad-based SCIINV Biosciences, incubated at ASPIRE BioNEST in the University of Hyderabad (UoH), signed an MoU with Microbira Ltd, a...
Hyderabad: Hyderabad-based SCIINV Biosciences, incubated at ASPIRE BioNEST in the University of Hyderabad (UoH), signed an MoU with Microbira Ltd, a UK-based biotech company, to combat antimicrobial resistance with an initial investment of £1 million.
According to UoH officials, this partnership strengthens the ties between the UK and India while addressing one of the most urgent global health challenges—antimicrobial resistance (AMR).
Gareth Wynn Owen, the British Deputy High Commissioner to Telangana and Andhra Pradesh, said, “The joint venture between SCIINV Biosciences and Microbira Ltd is a fantastic step forward in the fight against AMR.
It’s wonderful to see the UK-India innovation pipeline in action, and I’m particularly pleased that this partnership took shape following discussions during the UK’s Global Business Innovation Programme (GBIP) visit to India in June 2024. We’re excited to see the impact this will have in both countries and beyond.”
The joint venture is driven by a common vision: effective and rapid identification of microorganisms is critical for controlling the spread of drug-resistant infections. By developing a fast, accurate, and affordable identification platform, the partners aim to reduce the misuse of broad-spectrum antibiotics—a key contributor to AMR, particularly in India,” said Dr P Ratnakar, co-founder and director of SCIINV Biosciences.
